INTERNATIONAL BIOTECHNOLOGY TRUST PLC (the Company)
Amendments to the Top Ten Quoted Investments have been made to the 'Portfolio Update' announcement released on Friday, 27 April 2018 at 12:58 under RNS No 4257M.
All other details remain unchanged.
The full amended text is shown below.
Portfolio Update as at 31 March 2018
Net Assets |
£219m |
Net Assets per share |
584p |
Share price |
548p |
Total value of unquoted investments |
£21m |
Total number of portfolio companies |
90 |
Dividend |
4% of NAV per annum |
Top Ten Quoted Investments
Company Name |
% NAV |
Celgene |
6.0 |
Shire |
4.8 |
Array |
4.5 |
Neurocrine |
4.2 |
Biogen |
4.1 |
Regeneron |
4.0 |
Genmab |
3.9 |
Sage |
3.7 |
Vertex |
3.6 |
Gilead |
3.2 |
|
----------- |
Total |
42.0 |
Geographical Allocation |
% NAV |
US & Canada |
83 |
Europe & UK |
17 |
|
----------- |
Total |
100 |
Quoted/Unquoted Allocation |
% NAV |
Quoted |
91 |
Unquoted |
9 |
|
----------- |
Total |
100 |
NAV % Market Cap |
% NAV |
Large Cap >USD10BN |
36 |
Mid Cap =USD1-10BN |
37 |
Small Cap <USD1BN |
27 |
|
----------- |
Total |
100 |
NAV % by Therapeutic Areas |
% NAV |
Oncology |
42 |
CNS |
18 |
Rare diseases |
11 |
Inflammation |
7 |
Ophthalmology |
6 |
Infectious Diseases |
4 |
Metabolic |
3 |
Medtech |
3 |
Other |
6 |
|
----------- |
Total |
100 |
BNP Paribas Secretarial Services Limited
Company Secretary
30 APRIL 2018